EGUALEN SODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H17O3S.Na
Molecular Weight	300.348
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].CCC1=CC(=C2C=C(C=CC=C12)C(C)C)S([O-])(=O)=O

InChI

InChIKey=KXGWXVVNYQOMQZ-UHFFFAOYSA-M

InChI=1S/C15H18O3S.Na/c1-4-11-9-15(19(16,17)18)14-8-12(10(2)3)6-5-7-13(11)14;/h5-10H,4H2,1-3H3,(H,16,17,18);/q;+1/p-1

HIDE SMILES / InChI

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/23568973

Egualen is an azulene derivative developed for the treatment of peptic ulcer and marketed in Japan under the tradename Azuloxa. The drug exerts its antiulcer activity by antagonizing TXA2 production.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
thromboxane A2 signaling pathway 5 Target ID: GO:0038193 Sources: http://www.ncbi.nlm.nih.gov/pubmed/23568973	Antagonist 2849
gastric mucosal blood circulation 6 Target ID: GO:1990768 Sources: http://www.ncbi.nlm.nih.gov/pubmed/23568973	Activator 1447
mucus secretion 8 Target ID: GO:0070254 Sources: http://www.ncbi.nlm.nih.gov/pubmed/23568973	Activator 1447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Gastric ulcer 74 Sources: http://www.eisai.com/news/enews201620pdf.pdf	Primary		Approved 8583	AZULOXA Approved Use Unknown

C_max

Value	Dose	Analyte	Population
1272 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=23	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1417.7 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=23	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.6 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
0.58 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
1.84 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

AUC

Value	Dose	Analyte	Population
10744.1 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=23	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
11710.9 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=23	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
6 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
7.2 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
18.2 μg × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
7.8 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=23	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
7.9 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=23	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
4.6 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
5.9 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
4.4 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=24	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
1.7% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/2/270139_2323002D1032_2_006_1F.pdf#page=25 \| https://www.jstage.jst.go.jp/article/dmpk1986/5/3/5_3_375/_article/-char/en			EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
0.2% OTHER GOV'T https://www.jstage.jst.go.jp/article/dmpk1986/5/3/5_3_375/_article/-char/en	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:		EGUALEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
1.2 g 1 times / day multiple, oral Highest studied dose Dose: 1.2 g, 1 times / day Route: oral Route: multiple Dose: 1.2 g, 1 times / day Sources: https://www.giejournal.org/article/S0016-5107(13)00893-6/fulltext	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://www.giejournal.org/article/S0016-5107(13)00893-6/fulltext	Sources: https://www.giejournal.org/article/S0016-5107(13)00893-6/fulltext

PubMed

Title	Date	PubMed
A ring expansion-annulation strategy for the synthesis of substituted azulenes. Preparation and Suzuki coupling reactions of 1-azulenyl triflates.	2001-04-05	11277800
Inhibitory effect of egualen sodium: a new stable derivative of azulene on histamine release from mast cell-like cells in the stomach.	2001	11729358

Sample Use Guides

In Vivo Use Guide

1 tablet (15 mg) or 0.6 g of 2.5% granules twice a day.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

KT 1-32

Preferred Name

English

EGUALEN SODIUM

Common Name

English

1-AZULENESULFONIC ACID, 3-ETHYL-7-(1-METHYLETHYL)-, SODIUM SALT (1:1)

Common Name

English

3-ETHYL-7-ISOPROPYL-1-AZULENESULFONIC ACID SODIUM SALT

Common Name

English

Egualen sodium [WHO-DD]

Common Name

English

AZULETIL SODIUM

Common Name

English

SODIUM 3-ETHYL-7-ISOPROPYL-1-AZULENESULFONATE

Systematic Name

English

1-AZULENESULFONIC ACID, 3-ETHYL-7-(1-METHYLETHYL)-, SODIUM SALT

Common Name

English

Code System Code Type Description

EPA CompTox

DTXSID8048787